M1RN34 Stock Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Moderna, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.33 |
| 52 Week High | US$35.10 |
| 52 Week Low | US$16.70 |
| Beta | 1.59 |
| 1 Month Change | -1.41% |
| 3 Month Change | 10.83% |
| 1 Year Change | -17.61% |
| 3 Year Change | -43.79% |
| 5 Year Change | n/a |
| Change since IPO | 26.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| M1RN34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 4.2% | 0.6% | -0.2% |
| 1Y | -17.6% | -5.0% | 13.7% |
Return vs Industry: M1RN34 underperformed the BR Biotechs industry which returned -4.9% over the past year.
Return vs Market: M1RN34 underperformed the BR Market which returned 13.9% over the past year.
Price Volatility
| M1RN34 volatility | |
|---|---|
| M1RN34 Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.8% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: M1RN34 has not had significant price volatility in the past 3 months.
Volatility Over Time: M1RN34's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of BR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5,600 | Stephane Bancel | www.modernatx.com |
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.
Moderna, Inc. Fundamentals Summary
| M1RN34 fundamental statistics | |
|---|---|
| Market cap | R$209.93b |
| Earnings (TTM) | -R$24.34b |
| Revenue (TTM) | R$35.36b |
5.9x
P/S Ratio-8.6x
P/E RatioIs M1RN34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| M1RN34 income statement (TTM) | |
|---|---|
| Revenue | US$6.85b |
| Cost of Revenue | US$9.54b |
| Gross Profit | -US$2.69b |
| Other Expenses | US$2.02b |
| Earnings | -US$4.71b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -12.31 |
| Gross Margin | -39.28% |
| Net Profit Margin | -68.84% |
| Debt/Equity Ratio | 0% |
How did M1RN34 perform over the long term?
See historical performance and comparison